The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called efavirenz.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
16
Oral administration
Oral administration
Altasciences Clinical Kansas, Inc. (Site 0001)
Overland Park, Kansas, United States
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Nemtabrutinib
Blood samples will be collected to determine the AUC0-inf of nemtabrutinib.
Time frame: Predose and at designated time points (up to 2 weeks)
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Nemtabrutinib
Blood samples will be collected to determine the AUC0-24hr of nemtabrutinib.
Time frame: Predose and at designated time points (up to 24 hours postdose)
Maximum Plasma Concentration (Cmax) of Nemtabrutinib
Blood samples will be collected to determine the Cmax of nemtabrutinib.
Time frame: Predose and at designated time points (up to 2 weeks)
Time to Maximum Plasma Concentration (Tmax) of Nemtabrutinib
Blood samples will be collected to determine the Tmax of nemtabrutinib.
Time frame: Predose and at designated time points (up to 2 weeks postdose)
Apparent Clearance (CL/F) of Nembrutinib
Blood samples will be collected to determine the CL/F of nemtabrutinib.
Time frame: Predose and at designated time points (up to 2 weeks)
Apparent Volume of Distribution During Terminal Phase (Vz/F) Nemtabrutinib
Blood samples will be collected to determine the Vz/F of nemtabrutinib.
Time frame: Predose and at designated time points (up to 2 weeks)
Apparent Terminal Half-life (t1/2) of Nemtabrutinib
Blood samples will be collected to determine the t1/2 of nemtabrutinib.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Predose and at designated time points (up to 2 weeks)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 2 months
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 2 months